 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Passage Bio, Inc. (NASDAQ:PASG  Free Report)  Analysts at Chardan Capital increased their FY2023 earnings estimates for shares of Passage Bio in a research report issued to clients and...

Passage Bio, Inc. to Post FY2023 Earnings of ($1.61) Per Share, Chardan Capital Forecasts (NASDAQ:PASG)

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Passage Bio (NASDAQ:PASG  Get Free Report) had its price objective decreased by Raymond James from $9.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage...

Passage Bio (NASDAQ:PASG) PT Lowered to $5.00 at Raymond James

Passage Bio (NASDAQ:PASG  Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.49) EPS for the quarter, missing analysts consensus estimates of...

Passage Bio (NASDAQ:PASG) Issues Quarterly  Earnings Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Passage Bio expects cash to fund operations into 4Q25

Passage Bio reports Q3 EPS (49c), consensus (46c)

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with...

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Passage Bio (NASDAQ:PASG  Get Free Report) and Immatics (NASDAQ:IMTX  Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two...

Contrasting Passage Bio (NASDAQ:PASG) & Immatics (NASDAQ:IMTX)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Watchers	536
52-Wk Low	$0.5751
52-Wk High	$1.92

Market Cap	$34.81M
Volume (M)	35.00
52-Wk High	$1.92
52-Wk Low	$0.5751

PASG Passage Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals